Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 14,357

Document Document Title
WO/2021/090850A1
The present invention relates to a compound represented by general formula (1) or a salt thereof. In general formula (1), R1, R2, R3 and R4 are each independently a hydrogen atom, an optionally substituted straight-chain or a branched ...  
WO/2021/092096A1
Disclosed is an individualized dosing method of imaging the DAT receptors in a region of interest in the body of a subject using multiples of suboptimal packaging units of radiolabeled tracer, and kits for doing the same.  
WO/2021/087568A1
The present invention relates to compounds that are useful as radioimaging agents and radiopharmaceuticals. The compounds may be coordinated with a radionuclide and may be useful in diagnostic imaging and radiotherapy. The invention also...  
WO/2021/067749A3
Provided herein are methods and compositions for reducing inflammation and/or treating osteoarthritis in a patient in need thereof. The methods includes administering to the patient an inhibitor of an inflammation amplifying (Inf-A) popu...  
WO/2021/084087A1
The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer co...  
WO/2021/086962A1
Methods, kits, and compositions are described for the detection and treatment of premalignant lesions. This early detection allows patients to avoid the risks associated with repetitive imaging often employed to seek differentiation betw...  
WO/2021/078814A1
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The prese...  
WO/2021/081430A1
This disclosure relates to compounds of Formula IV: for fibrin imaging, wherein the compounds comprise an imaging or therapeutic radioisotope.  
WO/2021/080352A1
The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitril are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagno...  
WO/2021/080409A1
Human prostate tumours display intrinsic heterogeneity and changes in phenotype as the disease progresses, which involves various levels of cell-surface receptor expression. The invention relates to a new radiolabelled (Lys3)bombesina-iP...  
WO/2021/080008A1
The purpose of the present invention is to provide an Fc-modified antibody which has a long half-life in the blood and is obtained through a CCAP method. More specifically, the purpose of the present invention is to provide an antibody i...  
WO/2021/075544A1
This RI-labeled anti-MUC5AC humanized antibody is a complex of a radionuclide-chelated chelating agent and an antibody (the radionuclide is a metal nuclide that emits α-rays or positrons, and the antibody is a humanized antibody that bi...  
WO/2021/075546A1
The method for producing a radioactive metal-labeled antibody of the present invention has a step for click reacting a radioactive metal complex with an antibody site-specifically modified by a peptide to generate a radioactive metal-lab...  
WO/2021/071857A1
The disclosed embodiments provide a system that performs molecular assembly. During operation, the system delivers one or more droplets of a fluid onto a surface using a nanofluidic delivery probe and an associated high-precision positio...  
WO/2021/070029A1
A method of accumulating radium radionuclides, comprising providing a first solution including thorium radionuclides and a thorium-binding extractant, wherein the first solution does not bind to radium, allowing a portion of the thorium ...  
WO/2021/072103A1
Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of one or more immunoglobulin antibodies is elevated in an ...  
WO/2021/072235A1
Disclosed herein is a fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer. The dosing regimen may include a single dosing cycle or multiple dosing cycles. The radiation thera...  
WO/2021/069740A1
The invention relates to the field of radiation oncology. The method according to the invention comprises the use of botulinum toxin and an anticholinergic agent to prevent glands from radiation damage and side-effects due to radioligand...  
WO/2021/070164A1
A process for the preparation of a carrier-free Ga-68 solution from an irradiated Zn target, systems comprising components used in the process, and compositions comprising Ga-68 prepared by the process. Purification of Ga-68 is carried o...  
WO/2021/068051A1
There is provided bombesin-derived compounds of Formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX comprises a radionuclide chelator or a trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe, Cpa (4...  
WO/2021/061940A1
A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by...  
WO/2021/058758A1
The current invention relates to a cell composition comprising isolated mesenchymal stem cells, wherein said MSCs are radiolabeled with technetium-99m, wherein said radiolabel is essentially free of hexamethylpropylene amine oxime, and w...  
WO/2021/058549A1
The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting pharmaceuticals and their use in a theragnostic approach for selection and therapy of subjects with GRPR-expressing malignancies. In particular, the pr...  
WO/2021/055350A1
Radiolabeled anti-MET antibodies and MET x MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring...  
WO/2021/055638A1
Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that i...  
WO/2021/052960A1
The present disclosure relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is...  
WO/2021/055641A1
Fibroblast activation protein (FAP)-targeting compounds (e.g., conjugates); a method for imaging cancer or fibrosis; and methods for treating an inflammatory disease/disorder and cancer.  
WO/2021/053040A1
The present invention relates to methods for radiolabelling GRPR antagonists such as NeoB, and their kits. In particular, the invention to a method for labeling a gastrin-releasing peptide receptor (GRPR) antagonist with a radioactive is...  
WO/2021/055575A1
Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cel...  
WO/2021/055814A1
A method for detecting or ruling out non-small cell lung cancer (NSCLC) in a patient comprises: (a) administering to a patient a detectable amount of a compound of formula (I): Formula (I) wherein the compound is targeted to any NSCLC tu...  
WO/2021/030743A3
The present invention provides a compound of formula (I): A-B-C (I), wherein A is a hydrophobic moiety; B is a peptide, wherein the peptide forms a beta-sheet; and C is a hydrophilic targeting ligand, wherein the hydrophilic targeting li...  
WO/2021/051192A1
The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a li...  
WO/2021/046653A1
Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusio...  
WO/2021/002913A3
A device for synthesizing a radioisotope-labelled target tracer includes a microfluidic chip having an SCX module configured to concentrate and capture a radioisotope from a radioisotope solution and release the captured radioisotope the...  
WO/2021/046159A1
Provided are CD8 binding agents comprising a VHH domain that specifically binds human CD8. Also provided are nucleic acids encoding such CD8 binding agents, vectors comprising such nucleic acids, host cells comprising same, and methods o...  
WO/2021/046233A1
Provided herein are PMSA-binding molecules comprising a albumin-binding moiety and a chelating agent optionally chelating a therapeutic radioisotope or a PET-active, SPECT-active, or MR I -active radioisotope. The compound of Formula (II...  
WO/2021/046092A1
In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are compositions comprising Pol...  
WO/2021/038571A1
The present invention, in some embodiments thereof, is directed to an antigen binding polypeptide having increased binding affinity to prostate specific membrane antigen (PSMA). In some embodiments, the present invention is further direc...  
WO/2021/038596A1
Corticotropin releasing hormone peptide for positron emitting tomography imaging in Cushing's syndrome. The present invention discloses a composition for PET imaging in patients with Cushing's syndrome, to distinguish between Cushing's d...  
WO/2021/036022A1
A PET/CT tracer having selectivity for different lung cancer cells, a preparation method therefor and use thereof. The PET/CT tracer is a compound represented by formula I, or a salt or stereoisomer thereof, wherein R1 and R2 are each in...  
WO/2021/031930A1
Provided is a mutant of an antibody or fragment thereof, characterized in that the antibody or fragment thereof contains a light-chain constant region, and according to the Kabat numbering system, the amino acid at position 166 is mutate...  
WO/2021/034953A1
Compositions and methods for ablating CD206 expressing macrophages and/or CD206 expressing myeloid derived suppressor cells (MDSCs) are disclosed. In certain aspects, disclosed methods comprise administering to a subject in need thereof ...  
WO/2021/034943A1
Compositions and methods for in vivo immunoimaging IL-12 as a marker of IL- 12-producing activated antigen presenting cells (APCs) in a subject are provided according to aspects of the present disclosure which include: administering a la...  
WO/2021/034924A1
Featured are trans-cyclooctene and tetrazine compounds. Also provided are methods for evaluating the biodistribution and/or concentration of a biomolecule in a subject.  
WO/2021/032784A1
A compound comprising a bone-seeking agent capable of targeting bone of high metabolic activity (a pyrophosphate or a bisphosphonate) and a radiotoxic element (a Pt isotope, preferably 195mPt or 193mPt, more preferably 195mPt-isotope) is...  
WO/2021/007525A3
A nanoparticle agent includes a gold nanoparticle, at least one thiol modified Gd(III) macrocycle complex, and at least one prostate specific membrane antigen (PSMA) ligand, wherein the PSMA ligand and the thiol modified Gd(III) complex ...  
WO/2020/150617A8  
WO/2020/188478A8
The invention relates to rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al18F]2+ labelling of biomolecules. The chelating agents of the invention are used to form coordination complexes with ...  
WO/2021/026483A1
A new class of mass-tag polymers is provided, which include enriched metal isotopes such as zirconium and hafnium mass tags. The chemistry of these new mass tags are different from that of lanthanide mass tags, and opens up new mass chan...  
WO/2021/025984A1
Disclosed herein are compounds having a structure according to Formula I and optionally Formula IV. Formula I Formula IV. The compounds may be radiolabeled compounds useful for diagnosis and/or imaging fungal infections. In such embodime...  

Matches 1 - 50 out of 14,357